2-fluorohistidine: may serve as affinity labels & inactivators of receptor sites & enzymes; structure; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 308127 |
| SCHEMBL ID | 457889 |
| MeSH ID | M0051116 |
| Synonym |
|---|
| CBIOL_001041 |
| ICCB4_000337 |
| 2-fluorohistidine |
| l-histidine, 2-fluoro- |
| l-2-fluorohistidine |
| nsc208713 |
| 2fhis |
| 50444-78-5 |
| nsc-208713 |
| 2-amino-3-(2-fluoro-1h-imidazol-5-yl)propanoic acid |
| SCHEMBL457889 |
| OYHWICVZBUWSBK-UHFFFAOYSA-N |
| 2-fluoro-histidine |
| 2-amino-3-(2-fluoro-1h-imidazol-4-yl)propanoic acid |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||